Table 2 Clinical characteristics
Variable | Target population | CVOTs | ||
|---|---|---|---|---|
Number | Value | Number | Value | |
Duration of diabetes, years | 139,700 | 12.1 (9.4) | 71,636 | 11.7 |
Age, years | 139,708 | 68.8 (11.2) | 95,816 | 64.4 |
Sex male, % | 139,726 | 57.1 | 95,816 | 66.4 |
HbA1c, % mmol/mol | 132,717 | 7.3 (1.3) 56 (9) | 95,816 | 8.0 64 |
BMI, kg/m2 | 126,994 | 29.6 (5.5) | 95,816 | 31.6 |
Body weight, kg | 128,431 | 80.8 (17.1) | 39,332 | 89.1 |
Systolic blood pressure, mm Hg | 104,305 | 137.2 (18.4) | 64,572 | 135.6 |
Diastolic blood pressure, mm Hg | 104,226 | 77.5 (9.5) | 47,412 | 77.3 |
Established CVD, % | 139,726 | 28.9 | 95,816 | 67.5 |
PAD, % | 139,726 | 6.0 | 53,603 | 14.4 |
Previous MI, % | 97,074 | 11.7 | 50,820 | 38.8 |
Heart failure, % | 139,726 | 1.4 | 92,633 | 13.5 |
eGFR, ml/min/1.73 m2 | 113,593 | 75.7 (24.5) | 83,179 | 76.7 |
Albumin creatinine ratio, mg/g (median) | 113,775 | 22.6 | 41,064 | 1.4 |
Glucose-lowering therapy, % | 139,726 | 93.3 | 95,816 | 95.0 |
Insulin, % | 130,380 | 33.5 | 95,816 | 39.5 |
Metformin, % | 130,380 | 71.3 | 95,816 | 77.3 |
Sulphonylurea, % | 130,380 | 27.5 | 95,816 | 42.5 |
Thiazolidinediones, % | 130,380 | 5.0 | 78,656 | 4.1 |
DPP-4 inhibitors, % | 130,080 | 23.3 | 95,816 | 16.3 |
SGLT-2 inhibitors, % | 130,080 | 4.4 | 95,816 | 13.8 |
GLP-1 receptor agonists, % | 130,080 | 5.1 | 95,816 | 21.1 |
Anti-hypertensive therapy, % | 117,632 | 80.1 | 37,592 | 92.3 |
RAS blockers, % | 117,632 | 67.0 | 92,633 | 79.2 |
Calcium channel blockers, % | 117,632 | 25.1 | 49,080 | 32.8 |
Beta blockers, % | 117,632 | 31.5 | 92,633 | 56.7 |
Diuretics, % | 117,632 | 19.2 | 52,263 | 41.9 |
Statin, % | 117,632 | 61.1 | 95,816 | 75.3 |
Aspirin, % | 117,632 | 50.6 | 95,816 | 68.3 |